Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.OncoGenex has announced the final results of a randomized phase II trial. Analysis indicated a survival benefit in patients treated with OGX-011 in combination with docetaxel, as compared to docetaxel alone.
Subscribe to our email newsletter
The median overall survival in patients with advanced metastatic prostate cancer, who were treated with OGX-011 plus docetaxel in a randomized phase II trial, was 23.8 months compared to 16.9 months for patients treated with docetaxel alone, a 6.9 month observed survival advantage for the OGX-011 arm.
Dr. Chi, Principal Investigator of the NCIC-CTG sponsored trial at ASCO, said, A 6.9 month median overall survival difference would represent a significant improvement over the current standard docetaxel therapy.
Docetaxel was approved in 2004 based on a 2.4 month survival advantage in advanced prostate cancer. The consistent results in favor of the OGX-011 treatment arm in this trial are a clear indication that Phase 3 trials are warranted, he added.